Xian Xice Testing Technology Co. Ltd. A

Xice Testing released its 2026 interim report, showing total operating revenue of 156 million yuan, net profit attributable to the parent company of negative 57.282 million yuan, and net cash flow from operating activities of negative 17.5383 million yuan, a year-on-year decline of 244.75%. The company's asset-liability ratio was 45.48%, gross margin was 24.91%, return on equity was negative 6.29%, and diluted earnings per share was negative 0.68 yuan. The number of shareholders was 14,400, and the top ten shareholders held 64.55% of total share capital.

A-shares plunged over the past week. Harbin Pharmaceutical became the top-performing stock with a weekly gain of 58.16%, while Meixin Technology led the decline with a drop of 41.12%. Harbin Pharmaceutical disclosed on July 9 that its attributable net profit for the first half of 2026 is expected to increase by 46.40% to 68.36%, and that 118 of its product specifications have been included in the new edition of the National Essential Medicines List. The stock hit consecutive daily limit-up moves, but the limit was broken on July 17, closing up 7.89%. Meixin Technology saw profit-taking after its share price hit a record high, plunging over 41% for the week. Despite revenue growth in the first quarter, net profit fell 33.32% year-on-year. Coupled with a broad sell-off in tech stocks, the share price underwent a sharp correction. All ten stocks on this week's bear list posted weekly declines exceeding 39%, mostly due to concentrated capital outflows after prior highs.